49 results about "Chiral selectivity" patented technology

The invention discloses a carbonyl reductase mutant as well as a preparation method and application thereof, and belongs to the technical field of enzyme engineering. According to the invention, on the basis of carbonyl reductase BcKRED from Bacillus cereus, a series of dominant mutants are obtained through a method of directed evolution in the field of enzyme engineering. The carbonyl reductase dominant mutant obtained by the invention has high catalytic activity, thermal stability and chiral selectivity reversed with wild-type carbonyl reductase. A green and efficient way is provided for industrial production of chiral alcohol by taking carbonyl reductase as a biocatalyst, and the method has a wide application prospect.

The invention relates to the technical field of organic synthesis, in particular to a method for constructing Orforglipron tetrahydropyran ring chirality through enzyme catalysis, which comprises the following steps: step S1, taking SM1 as a raw material, and carrying out hydrolysis resolution in a solvent, a buffer salt system and enzyme catalysis to obtain a chiral pure intermediate INT-1; step S2; performing ring closing on the INT-1 through Grignard reaction to synthesize a lactone intermediate; s3, carrying out Diball-H reduction, quenching, dichloromethane extraction and anhydrous sodium sulfate drying on the INT-4, and then reducing the INT-4 by using triethyl silane to obtain an intermediate INT3; step S4, coupling the INT-3 in the presence of a catalyst and a ligand to obtain an intermediate INT-4; step S5, carrying out deprotection and salification on the INT-4 to obtain an intermediate INT5; s6, closing an indole ring from INT5 to obtain a compound of which the general formula is A; chirality is constructed through enzyme catalysis, isomer impurities do not need to be split and separated through SFC when the chirality is constructed, the loss is reduced, the yield is increased, and a target product is obtained with high chiral selectivity; meanwhile, the cost is relatively reduced, and the cost is saved.

The present invention relates to the technical field of organic synthesis, and specifically relates to a method for constructing the chirality of a pyran ring in Orforglipron by means of enzymatic catalysis, the method comprising the following steps: step S1, by using SM1 and SM2 as starting materials, carrying out a reaction under the action of a palladium catalyst and a ligand to obtain INT-1; step S2, under the catalysis of Pd / C, subjecting INT-1 to double bond hydrogenation reduction to obtain INT-2; step S3, in the presence of a solvent, a buffer salt system and enzymatic catalysis, subjecting INT-2 to hydrolysis and resolution to obtain a chirally pure intermediate INT-3; step S4, subjecting INT-3 to a Grignard reaction for cyclization, so as to synthesize a lactone intermediate INT-4; and step S5, subjecting INT-4 to reduction by means of Dibal-H, quenching same, performing extraction with dichloromethane, drying same with anhydrous sodium sulfate, and then performing reduction by means of triethylsilane to obtain a compound of general formula A. In the present invention, the chirality is constructed by means of enzymatic catalysis without the need of SFC resolution for separating isomeric impurities during the construction of the chirality, thereby reducing losses and improving yield, obtaining the target product at high yield and high chiral selectivity, and further saving expenses and reducing costs.

The present invention relates to the field of pharmaceutical technologies, and specifically, to a preparation method of finerenone and its key intermediate. The present invention uses enzymatic resolution to prepare the key chiral intermediate (S)-compound of formula I of finerenone. The present invention has the advantages of high chiral selectivity in the reaction, being green and environmentally friendly, high yield, and not requiring the use of chromatographic separation technology, and is suitable for industrial production, etc.

The invention discloses a preparation method and application of a chiral phosphoric acid intrinsic microporous polymer membrane. In the invention, R / S-1, 1 '-co-2-naphthol and indole-2, 3-dione or a derivative thereof are taken as monomers, and the soluble chiral polymer with an intrinsic microporous structure is prepared through catalytic polymerization. After the polymer forms a film, phosphorylation treatment is carried out, a phosphate group is introduced, and the chiral phosphoric acid intrinsic microporous polymer film is obtained. The membrane has high specific surface area and chiral recognition sites, shows excellent enantiomer selectivity and permeability, can be widely applied to efficient separation of chiral small molecular enantiomers, has important application value and popularization prospect in the field of chiral separation, can simultaneously realize integration of microporous channels, chiral environments and multifunctional phosphate groups, and has broad application prospects. Therefore, breakthrough balance is achieved between chiral selectivity and permeation flux, and a new material platform is provided for chiral membrane separation.

The application belongs to the technical field of antitumor drugs, and particularly relates to an AuNRs@L / D-Ag2S QDs complex, a preparation method and application thereof. Sodium polystyrene sulfonate is electrostatically adsorbed on AuNRs to obtain 1-PSS-AuNRs; polyallylamine hydrochloride is electrostatically adsorbed on 1-PSS-AuNRs to obtain 2-PAH-AuNRs; polyallylamine hydrochloride is electrostatically adsorbed on 2-PAH-AuNRs to obtain a non-chiral nanomaterial; and the non-chiral nanomaterial is covalently crosslinked with L / D-Ag2S QDs to obtain the AuNRs@L / D-Ag2S QDs complex. The application combines the efficient photo-thermal conversion characteristics of AuNRs with the chiral-dependent targeting and potential fluorescence imaging ability of chiral Ag2S quantum dots by constructing a complex structure, so that a novel nanodiagnostic and therapeutic agent with efficient photo-thermal performance and chiral selectivity is obtained.

The invention discloses a method for preparing an Aficamten intermediate by adopting an enzyme method. The method comprises the step of preparing a chiral intermediate compound as shown in a formula II from a compound as shown in a formula I under enzyme catalysis. The method greatly shortens the synthesis route and period, and is simple in post-treatment, simple to operate, high in yield, high in chiral selectivity, green, environment-friendly and suitable for industrial production.

The present invention relates to a novel route for preparing oxopyridine compounds shown in formula (I) and their key intermediates. The novel route provided by the present invention can greatly reduce the generation of isomeric impurities, improve the chiral selectivity of the reaction and the N / O-alkylation selectivity, increase the yield, eliminate the need for further purification of the crude product, reduce the cost, shorten the production cycle, save energy and protect the environment, and is suitable for use in the preparation of drugs for treating and / or preventing diseases related to the FXIa receptor, especially providing a new idea for the preparation of drugs for treating and / or preventing cerebrovascular arterial diseases and / or peripheral arterial diseases.

The invention belongs to the field of medical intermediate compounds and organic synthesis, and particularly relates to a key intermediate of lotinib and a preparation method thereof, the preparation method comprises the following steps: (1) in an organic solvent, organic alkali, 2-cyanoethyl 5-acetyl-3-methylthiophene-2-carboxylic ester and 2, 2, 2-trifluoro-1-(3, 4, 5-trichlorobenzene) ethanone react to obtain an intermediate 1; (2) dehydrating the intermediate 1 into double bonds to obtain an intermediate 2; and (3) reacting the intermediate 2 with a ligand to obtain the key intermediate of lotinib. The intermediate is used for synthesizing lotinib. The preparation method provided by the invention has the advantages of extremely high chiral selectivity, mild conditions and stable yield, can be suitable for amplified production, and provides a new technology suitable for industrial production for the key intermediate of lotinia.

The present application relates to ticagrelor intermediates and a preparation method thereof, wherein a halogenated group of compound VI is removed by a deacidifying agent to open a ring, process conditions are simple, and operation is easy; meanwhile, a chiral center in a molecule is constructed by using a transaminase to prepare compound VII from compound VI, conditions are more mild, chiral selectivity is better, raw material utilization is improved, chiral separation or chiral reduction process is avoided, and industrialized production is more beneficial. The disclosed technical scheme can be connected with a process for preparing compound VII from D-ribose as a starting material, forming a process for preparing target compound ticagrelor intermediate compound VII from compound I (D-ribose) as a raw material, synthesizing compound II by reacting with methanol, then synthesizing compound III by sulfonylization of compound II, then synthesizing compound IV by halogen substitution of compound III, and further opening a ring, closing a ring, and catalyzing by a transaminase.

The invention belongs to the field of bioengineering and food technology, and discloses a method for enzymatic resolution of chiral substances, including the following steps: (1) preparing an enzyme solution with a lipase concentration of 1-3000 U / mL, and adding a soluble salt, a hydrophilic solvent and a hydrophobic solvent to the enzyme solution to form a three-liquid phase system; the hydrophobic solvent contains esters or amide compounds composed of racemic chiral compounds; (2) subjecting the three-liquid phase system to enzyme-catalyzed reaction under stirring condition; after the reaction is completed, standing or centrifuging the three-liquid phase system to divide it into three layers, which are a upper liquid layer, a middle liquid layer and a lower liquid layer from top to bottom. The optically pure chiral product after hydrolysis is mainly rich in the middle liquid layer or the lower liquid layer, while the upper liquid layer product is another ester or amide product containing an optically pure chiral product. The method has the advantages of low energy consumption, high raw material utilization rate, and mild reaction conditions, and solves the problems of low chiral resolution efficiency, poor chiral selectivity, low recovery rate, and difficulty in industrialization in the existing enzymatic method.

The present invention relates to a novel route for preparing oxopyridine compounds represented by formula (I) and their key intermediates. This novel route significantly reduces the generation of isomeric impurities, improves reaction chiral selectivity and N / O-alkylation selectivity, and enhances yield. It is particularly effective for chemical resolution of novel structures in which R1 is a non-hydrogen group. The resulting crude product eliminates the need for costly chiral purification (SFC), reducing costs, shortening production cycles, and being energy-efficient and environmentally friendly. The novel route is suitable for preparing drugs for treating and / or preventing diseases associated with the FXIa receptor, and in particular, provides a novel approach for preparing drugs for treating and / or preventing cerebrovascular arterial disease and / or peripheral arterial disease. #imgabs0#

The present invention discloses a method for synthesizing an edoxaban intermediate. First, the raw material (S)-(−)-3-cyclohexene carboxylic acid is oxidized by potassium permanganate to generate intermediate 2; intermediate 2 reacts with methanesulfonyl chloride to generate intermediate 3; intermediate 3 reacts with ammonia in ethanol to generate intermediate 4; intermediate 4 undergoes a self-cyclization reaction under the catalysis of EDCI and HOBt to generate intermediate 5; intermediate 5 reacts with benzyl chloride to generate intermediate 6; intermediate 6 is hydrolyzed under alkaline conditions and reacts with Boc2O simultaneously to generate intermediate 7; intermediate 7 undergoes a condensation reaction with dimethylamine to generate intermediate 8; intermediate 8 is hydrogenated to remove the benzyl group to generate the edoxaban intermediate. The synthesis method of the present invention has simple operation steps, high chiral selectivity, is beneficial to improving the product yield and reducing the production cost, and does not use the dangerous reagent sodium azide, reducing the production risk and ensuring the safety and operability of the reaction.

The invention discloses a novel chiral covalent organic framework mimic enzyme catalyst and its preparation method and application, the preparation method comprises the following steps: 1,3,5-tris (4-aminophenyl) benzene, 2,5-bis (prop-2-yn-1-yloxy) terephthalaldehyde and dialdehyde monomers with different functional groups are dissolved in an organic solvent, an acetic acid aqueous solution is added, and the reaction is carried out at 80-120 DEG C for 2-4 days to obtain a three-component covalent organic framework material with different properties, and then a small molecule catalyst, i.e., a proline derivative, is fixed in the framework by a click reaction, and then washed, dried and deprotected to obtain a chiral covalent organic framework catalyst. The chiral covalent organic framework material prepared by the present invention is used as a heterogeneous catalyst for asymmetric aldol condensation reaction in a green solvent aqueous phase, showing good catalytic effect and chiral selectivity. After the reaction, the catalyst can be separated and recovered by simple centrifugation or filtration, effectively reducing environmental pollution, while reducing costs, and having good application prospects.

The application discloses a hydrazone chiral covalent organic framework material and a preparation method thereof. The preparation method comprises the following steps: under an inert atmosphere, a chiral hydrazine precursor with a tert-butyloxycarbonyl protection group is dissolved in an organic solvent together with 2,4,6-tris(4-formylphenyl)-1,3,5-triazine, and then an aqueous acetic acid solution is added, and the mixture is reacted at 90-120 DEG C for 2-5 days; then, insoluble substances are collected, and after washing, drying and deprotection treatment, the hydrazone chiral covalent organic framework material is obtained. The hydrazone chiral covalent organic framework material prepared by the application is used as a heterogeneous catalyst for asymmetric reaction, and exhibits good catalytic effect and chiral selectivity, and also has good chemical stability; after the reaction, the catalyst can be separated and recovered through simple centrifugation or filtration, so that environmental pollution is effectively reduced, the cost is reduced, and the application prospect is good.

The invention discloses a high-efficiency rotigotine preparation process which comprises the following steps: dissolving sodium triacetoxyborohydride in a reaction solvent, adding 2-thiopheneethylamine while stirring, dropwise adding a dichloromethane solution of 5-methoxy-2-tetralone, continuously reacting, and carrying out post-treatment to obtain N-(1, 2, 3, 4-tetramethyl-4-piperidine)-1, 2, 3, 4-tetramethyl-4-piperidine. The preparation method comprises the following steps: adding 2, 2, 4-tetrahydro-5-methoxy-2-naphthyl)-2-thiophene ethylamine; dissolving L-DTTA and L-DBTA in ethanol and a water solvent, adding into the product, carrying out a reflux reaction, and recrystallizing to obtain a single-configuration resolution salt; the preparation method comprises the following steps: adding sodium triacetoxyborohydride into a reaction kettle, carrying out product alkalization, carrying out methyl tertiary ether extraction, concentrating an organic layer until the organic layer is dry, dissolving with dichloromethane, adding sodium triacetoxyborohydride, dropwise adding propionaldehyde, continuously carrying out stirring reaction after dropwise adding, after the reaction is finished, concentrating until no liquid drop exists, and carrying out post-treatment to obtain (S)-5-methoxyrotigotine; and dropwise adding HBr, and recrystallizing with n-hexane to obtain rotigotine. According to the present invention, the STAB-mediated continuous reductive amination is adopted to replace the high pressure hydrogenation, and the L-DTTA / L-DBTA composite resolution system is designed to improve the chiral selectivity, such that the process is simplified, and the cost is reduced.

The invention discloses a method for synthesizing an amatoxin intermediate through Rh / Cu concerted catalysis, and belongs to the technical field of allylic alkylation reaction, an Rh / Cu concerted catalysis system is used for carrying out chiral selectivity and stereoselectivity allylic alkylation reaction on p-diphenyl imine glycine tert-butyl ester and racemic carboxylic acid allyl ester, and the amatoxin intermediate is synthesized. The rhodium catalyst controls the configuration of electrophilic carbon atoms in allyl ester, the copper catalyst controls the configuration of nucleophilic carbon atoms in unstable enol salt, and finally the amatoxin intermediate is obtained. According to the method for synthesizing the amatoxin intermediate through Rh / Cu concerted catalysis, an Rh / Cu concerted catalysis system can achieve ortho-position three-level three-dimensional center construction, multiple aryl and aliphatic substituted branched chain allyl products are obtained through the Rh / Cu concerted catalysis system, the yield is good or higher, cis-trans isomerization selectivity is high, and the method is suitable for industrial production. The enantiomeric selectivity is good to excellent.

The present invention provides a series of monoamine oxidases (PMAON) with high catalytic activity and strong chiral selectivity, which are derived from Penicillium, as well as a method for stereoselectively preparing 6,6-dimethyl-3-azabicyclo[3.1.0]hexene compounds using the enzyme. The present invention also provides genes encoding the series of monoamine oxidases, recombinant expression vectors containing the series of genes, recombinant expression transformants and methods for preparing the same.

The invention provides an amidase mutant and application thereof in preparation of (S)-penthiopyrad, and belongs to the technical field of gene engineering and enzyme catalysis. Compared with amidase with an amino acid sequence as shown in SEQ ID No.1, the amidase mutant disclosed by the invention comprises one or more site mutations as follows: alanine at the 132 site is mutated into leucine; serine at the 205th site is mutated into glycine; the alanine at the 211 site is mutated into glycine. Compared with wild amidase, the amidase mutant disclosed by the invention has the advantages that the enzyme activity and stereoselectivity are obviously improved; the preparation method based on the mutant is mild in process and simple and convenient to operate, and the obtained (S)-penthiopyrad has excellent chiral selectivity and product optical purity, conforms to the development trend of green pesticide creation and has important industrial application value.

This application discloses a polarization-independent chiral selective reflection and multidimensional optical field modulation device and method, relating to the fields of integrated photonics and micro / nano optics. The device includes: a geometrically phased liquid crystal layer, a transparent capping layer, a chiral metasurface array layer, a dielectric substrate layer, and a total reflection layer; wherein, the chiral metasurface array layer can break the in-plane mirror symmetry and exhibit chiral selective reflection characteristics in the target wavelength band. The geometrically phased liquid crystal converts the polarization state of arbitrary incident light into orthogonal left-handed and right-handed circularly polarized light. The chiral metasurface array layer selectively reflects one type of circularly polarized light while absorbing another type of circularly polarized light with the opposite chirality. The reflected circularly polarized light exits through the geometrically phased liquid crystal, achieving two-way phase modulation. This invention achieves geometrically phase modulation by four times the rotation angle of liquid crystal molecules, and has the advantages of compact structure, low crosstalk, low cost, and easy integration with semiconductor processes.

The present invention discloses a ketoreductase. The present invention also discloses its application in the in vitro biosynthesis of (R)-6-hydroxy-8-chlorooctanoic acid ethyl ester. As a biocatalyst, it converts 8-chloro-6-oxooctanoic acid ethyl ester into (R)-6-hydroxy-8-chlorooctanoic acid ethyl ester with excellent chiral selectivity, bringing the corresponding chirality into the synthesis route, greatly reducing production costs, eliminating the environmental impact generated during the by-product treatment process, and is simple to operate, mild in conditions, and short in time. The conversion rate and product purity are both above 87%, making it suitable for industrial application.

The application relates to the technical field of nanochannel filter membrane, in particular to a filter membrane loaded with Mb-COF nanochannels and a preparation method thereof. The preparation method introduces 2D COF into the cylindrical nanochannel through in-situ growth technology, then based on the pore size matching effect, Mb is modified into the COF nanochannel loaded on the filter membrane, a filter membrane loaded with Mb-COF nanochannels with chiral selectivity is obtained, the filter membrane loaded with Mb-COF nanochannels is expected to be used for separating and / or detecting the selective transport of chiral drug molecules through the membrane, the preparation method has mild reaction conditions, simple operation, and is easy to popularize and use.

The invention provides a chiral electrochemical sensor based on beta-cyclodextrin / cerium-doped copper-based metal organic framework / carboxylated multi-walled carbon nanotube (beta-CD / Ce-doped Cu-MOF / MWCNTs-COOH), a preparation method of the chiral electrochemical sensor, and a detection method for carrying out chiral recognition on an ofloxacin enantiomer by using the sensor. According to the chiral electrochemical sensor, a glassy carbon electrode is used as a substrate, a composite conducting layer of a carboxylated multi-walled carbon nanotube (MWCNTs-COOH) and a cerium-doped copper-based metal organic framework (Ce-doped Cu-MOF) is modified firstly, and then a beta-cyclodextrin (beta-CD) chiral recognition layer is modified on the surface through an electrochemical polymerization method. According to the design, the electro-catalytic activity of the Ce-doped Cu-MOF, the high conductivity of the MWCNTs-COOH and the chiral selectivity of the beta-CD are integrated, so that a synergistic enhancement effect is generated. By utilizing the sensor and combining a linear sweep voltammetry (LSV), high-sensitivity and high-selectivity detection of levofloxacin can be realized. The method has the advantages of being simple in instrument, easy and convenient to operate, rapid in detection, high in sensitivity, high in selectivity, good in stability and the like, is suitable for rapid analysis of levofloxacin in pharmaceutical preparations, food and environmental samples, and has wide application prospects in the fields of drug quality control and safety monitoring.

The invention discloses a design and construction method and application of a novel Friedel-Crafts alkylating enzyme based on non-natural cysteine, and belongs to the technical field of synthetic biology. According to the present invention, the 15th valine of the enzyme LmrR is replaced with p-aminobenzene cysteine to construct the artificial enzyme LmrRpAPhC, the mutant with improved chiral selectivity is further obtained through site-specific mutagenesis, and the ee value of the mutant LmrRV15pAPhCF93L achieves 82 + / -0%, and is improved by 20% compared with the ee value before mutation. Good application prospects are shown.

The present invention provides a paroxysmal hemoglobinuria indication drug ipropam key intermediate synthesis method, and relates to the technical field of ipropam, the method comprises: taking p-bromobenzaldehyde as an initial raw material, adopting an organic catalyst to obtain an intermediate 03, carrying out protection group removal on the intermediate 03, carrying out automatic ring closing to obtain an intermediate 04, and carrying out post-treatment to obtain the paroxysmal hemoglobinuria indication drug ipropam key intermediate. Reducing the intermediate 04 with sodium borohydride to obtain a single cis-configuration intermediate 05, then carrying out a chiral flip reaction and hydrolysis to remove p-nitrobenzoic acid, then carrying out an etherification reaction with diethyl sulfate to obtain an intermediate 08, reducing amide of the intermediate 08 with sodium borohydride and boron trifluoride diethyl etherate to obtain an intermediate 09, then carrying out an acetylation reaction to protect amino, and finally carrying out a reaction to obtain the chiral cis-configuration intermediate 03. Cuprous cyanide is subjected to a cyanation reaction and a hydrolytic esterification reaction to obtain the ipropam key intermediate TM. The method is low in raw material price, high in chiral control selectivity, easy in reaction condition control and low in equipment requirement, avoids column chromatography and other operations, and is more suitable for industrial production.

The invention discloses a pair of one-driving-two binocular different-display ultrathin AR glasses based on geometric phase optical integration, which comprises an optical engine module and a waveguide display module, and is characterized in that the optical engine module comprises a display chip and a collimation optical system, and the display area of the display chip is divided into a first sub-image area and a second sub-image area; the waveguide display module comprises a polarization sensitive diffraction coupling element, a first waveguide display lens and a second waveguide display lens, the polarization sensitive diffraction coupling element adopts a geometric phase element, and diffracts and splits a collimation linear polarized light beam into + 1 level and-1 level diffracted light with opposite rotation directions; image information carrying the two sub-image areas is coupled into the corresponding waveguide display lenses, and chiral selective coupling out is achieved through the polarizer holographic grating. The binocular different display function can be achieved only through a single light engine module, the size, weight, power consumption and cost of the system are reduced, and meanwhile the problem that consistency calibration of a left-eye optical system and a right-eye optical system in a double-light-engine scheme is difficult is solved.

The invention relates to the technical field of asymmetric hydrogenation, and particularly discloses a preparation method of a nebivolol intermediate, the nebivolol intermediate is prepared by adopting asymmetric hydrogenation reaction, the method has remarkable technical advantages, extremely high catalytic activity is realized by selecting a catalytic system composed of a specific chiral phosphine ligand and rhodium salt, and the method is suitable for industrial production. According to the present invention, the molar ratio (S / C) of the substrate to the catalyst is as high as 30,000, the production cost is significantly reduced, the process has characteristics of excellent chiral selectivity and excellent reaction efficiency, the e.e value of the product can achieve more than 99%, the yield is excellent, the yield loss caused by the traditional resolution process is effectively avoided, and the method has characteristics of good compatibility with a variety of organic solvents, and can be used for industrial production. By adding the alkaline auxiliary agent, the reaction effect can be further improved, the process is stable, and the industrial application value is relatively high.

The invention belongs to the technical field of organic synthesis, and discloses an application of a chiral phosphine-nitrogen-nitrogen tridentate ligand in asymmetric allyl substitution reaction, the chiral phosphine-nitrogen-nitrogen tridentate ligand is constructed by taking ferrocene as a skeleton, the ligand has a plurality of chiral factors and has a potential hydrogen bond donor, and the chiral phosphine-nitrogen-nitrogen tridentate ligand has a high chiral selectivity. In an allyl substitution reaction, the compound can form a hydrogen bond with a hydrogen bond acceptor of a substrate. Therefore, the ligand disclosed by the invention has the advantages of high reaction activity, good stereoselectivity, wide substrate range and the like in asymmetric allylic substitution reaction.

This invention provides a ketone reductase mutant and its application in the synthesis of a key chiral intermediate for ticoraxene. The mutant contains amino acid sequences such as SEQ ID NO: 4, 6, 8, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, or 42. This ketone reductase mutant exhibits higher carbonyl catalytic activity and chiral selectivity than the wild type, and is used in the preparation of the key intermediate R-5,7-difluorobenzodihydropyran-4-ol for ticoraxene.

This invention relates to a chiral metal supramolecular compound, a pharmaceutical composition, and their application in treating monkeypox virus, belonging to the field of medicinal chemistry. To address the technical problems of neurotoxic side effects and poor drug-likeness in existing drugs used to treat or prevent poxviruses, this invention provides a chiral metal supramolecular compound and a pharmaceutical composition containing the above compound, wherein the chiral metal supramolecular compound is [Fe2L3]. 4+ The Λ enantiomer, abbreviated as MH3-Λ, has chiral selectivity and is more selective for monkeypox virus RNA than MH3-Δ. On the one hand, it can enhance the stability of A5L mRNA and the expression of the 39kDa core protein of monkeypox virus. On the other hand, it can also enhance the immune response induced by monkeypox virus, reduce the production of monkeypox virus, and prevent the further spread of monkeypox virus to the surrounding environment. It can be used to prepare anti-monkeypox drugs.